317 related articles for article (PubMed ID: 35595166)
1. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families.
Li L; Meyer C; Zhou ZW; Elmezayen A; Westover K
J Mol Biol; 2022 Sep; 434(17):167626. PubMed ID: 35595166
[TBL] [Abstract][Full Text] [Related]
2. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
3. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
4. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
5. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
6. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
7. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
9. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
10. Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases.
Bhujbal SP; Jun J; Park H; Moon J; Min K; Hah JM
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731943
[TBL] [Abstract][Full Text] [Related]
11. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
12. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
13. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.
Nussinov R; Zhang M; Maloney R; Liu Y; Tsai CJ; Jang H
J Mol Biol; 2022 Sep; 434(17):167569. PubMed ID: 35378118
[TBL] [Abstract][Full Text] [Related]
14. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
[TBL] [Abstract][Full Text] [Related]
16. The reactivity-driven biochemical mechanism of covalent KRAS
Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
Cowan-Jacob SW; Jahnke W; Knapp S
Future Med Chem; 2014 Apr; 6(5):541-61. PubMed ID: 24649957
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
19. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
20. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
